펄스 필드 절제 시장 : 치료 영역별, 제품 컴포넌트별, 응용 영역별, 절제 근원별, 주요 지역별, 주요 기업의 시장 점유율 : 업계 동향과 세계 예측(2023-2035년)

Pulsed Field Ablation Market by Therapeutic Area, Product Components, Application Areas, Source of Ablation, and Key Geographical Regions: Market Share of Key Companies, Industry Trends and Global Forecasts, 2023-2035

US $ 4,799 ￦ 6,810,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,999 ￦ 9,932,000

PDF (One-Location Site License)

PDF 보고서를 동일 사업장의 특정 사업 부문에 속한 모든 분들이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 10,599 ￦ 15,041,000

PDF (Department License)

PDF 보고서를 부서 단위로 12명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 17,999 ￦ 25,542,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

심방세동(AF)은 세계에서 남녀 모두에게 가장 흔하게 발생하는 지속성 부정맥입니다. 심방세동 유병률은 일반 인구에서 연령이 증가할수록 증가하는 경향을 보입니다. Global Burden of Disease, Injury and Risk Factor Study 2019에 따르면 세계에서 5,970만 명의 환자가 심방세동 진단을 받았으며, 뇌졸중 위험은 5배, 사망 위험은 2배 더 높습니다. 고령자는 심방세동 발병 위험이 높기 때문에 세계 인구의 고령화는 심방세동 유병률의 급격한 증가를 위협하고 있습니다. 미국에서는 65세 이상 인구의 약 9%가 심방세동을 앓고 있습니다. 유럽에서 심방세동은 주요 공중보건 문제 중 하나로 부상하고 있으며, 지난 10년간 그 유병률이 두 배로 증가했습니다. 유럽 국가들은 고령화가 빠르게 진행되고 있으며, 향후 10년간 심방세동 환자 수는 70% 증가할 것으로 예측됩니다. 또한 심방세동 발견과 진단이 개선되면서 심방세동 보고 건수 증가에 기여하고 있습니다. 또한 빠르게 증가하는 심방세동 유병률에는 현대인의 생활습관과 관련된 여러 가지 위험요인이 관여하고 있습니다. 이러한 위험 요인에는 고혈압, 당뇨병, 흡연, 음주, 비만, 운동 부족, 심리적 스트레스 등이 포함됩니다. 비열적 치료법인 펄스 필드 절제술은 심방세동 환자에게 안전한 치료법으로 입증되고 있습니다.

현재 심혈관계 질환, 종양성 질환, 호흡기 질환, 피부 질환 등의 치료 응용을 위해 여러 가지 펄스 자기장 절제 장비가 사용 가능하고 개발 중입니다. 특히 펄스 자기장 절제 장비는 심근 조직에 대한 선택성을 보여 식도 손상, 폐정맥 협착, 호흡 신경 마비의 위험을 줄이면서 심장 부정맥의 치료 및 관리에 높은 효능을 보이고 있습니다. 다양한 유형의 심장 부정맥 중 PFA 절제술은 심방세동(지속성 및 발작성)을 관리하기 위한 입증된 방법입니다. 심방세동은 심장의 심방(위쪽 방)의 불규칙한 박동으로 인해 혈액이 심실(아래쪽 방)로 흐르지 않는 것이 특징이며, PFA 절제술은 주로 폐정맥 격리술(PVI)을 통해 심방세동을 유발하는 비정상적인 전기적 신호의 원인인 폐정맥을 표적으로 삼아 격리하여 PVI 시술은 전극이 달린 카테터를 혈관을 통해 심장에 삽입하여 정상적인 심장 리듬을 되찾는 것을 목표로 합니다. 이 카테터는 폐정맥까지 유도되고, 전극은 폐정맥 주변 조직에 제어된 전기 펄스를 공급합니다. 이 전기 펄스는 병변과 흉터 조직을 형성하여 비정상적인 전기 신호가 심방의 다른 부분으로 전달되지 않도록 차단합니다. 심방세동뿐만 아니라 심실빈맥, 심방조기박동 등 다른 부정맥 치료에도 펄스 필드 절제술이 적용될 수 있다는 점을 강조하고 싶다.

종양학 분야에서 펄스 필드 절제술은 악성 종양을 포함한 광범위한 고형 종양을 치료하는 데 사용되었습니다. 전기 펄스의 적용은 종양의 미세 환경을 변화시켜 종양 세포를 죽이고, 면역 체계를 동원하여 종양의 성장과 침윤을 억제함으로써 종양에 대한 억제 효과를 유도할 수 있습니다. 또한 기도의 염증을 특징으로 하는 만성 기관지염은 기관지 내벽을 덮고 있는 점액 생성 세포를 PFA로 표적 절제하여 치료할 수 있습니다. 펄스 필드 절제술은 피부과 영역에서 큰 진전을 이루었으며, 양성 및 전암성 증식을 포함한 피부 병변을 정확하게 제거하는 효과적인 접근 방식을 제공합니다. 이러한 유형의 절제 기술의 조직 선택성은 피부의 비세포성 콜라겐 기반을 보존하고 표적 세포의 재생을 가능하게 합니다.

심방세동 유병률 증가, 비가역적 전기자극 절제술의 높은 효과와 안전성 프로파일을 고려할 때, 펄스필드 절제술 시장 규모는 예측 기간인 2023-2035년까지 약 40%의 CAGR로 확대될 것으로 예상됩니다. 치료 분야별로는 2023년 심혈관계 질환 분야가 펄스필드 절제술 시장에서 가장 큰 시장 점유율을 차지할 것으로 예상되며, 이러한 추세는 예측 기간 중 변함없이 유지될 것으로 보입니다.

세계의 펄스 필드 절제 시장에 대해 조사했으며, 시장의 개요와 치료 영역별, 제품 컴포넌트별, 응용 영역별, 절제 근원별 동향, 지역별 동향 및 시장에 참여하는 기업 개요 등을 제공하고 있습니다.

목차

제1장 서문

제2장 조사

조사 방법

제3장 경제 및 기타

프로젝트 특유 고려사항

제4장 주요 요약

제5장 서론

제6장 펄스 필드 절제 디바이스 : 시장 구도

제7장 제품의 경쟁력 분석

• 챕터 개요
• 가정과 주요 파라미터
• 조사 방법
• 제품의 경쟁력 분석 : 펄스 필드 절제 디바이스
• 결론

제8장 펄스 필드 절제 디바이스 개발자 : 상세

기업 개요

• 챕터 개요
• Boston Scientific
• Medtronic
• Galvanize Therapeutics
• Pulse Biosciences
• AngioDynamics
• Biosense Webster
• Acutus Medical
• Kardium

제9장 펄스 필드 절제 디바이스 개발자

기업 개요

• 챕터 개요
• Abbott
• AccuPulse Medical
• Arga Medtech
• AtriAN Medical
• AuriGen Medical
• CathRx
• ElectroPhysiology Frontiers
• EnChannel Medical
• Hangzhou Dinova EP

제10장 최근 개발과 구상

제11장 특허 분석

제12장 세계의 이벤트 분석

제13장 사례 연구 : 펄스 필드 절제 디바이스 개발자의 잠재적 파트너

제14장 시장에 대한 영향 분석 : 촉진요인, 촉진요인, 기회, 과제

• 챕터 개요
• 시장 촉진요인
• 시장 억제요인
• 시장의 기회
• 시장이 해결해야 할 과제
• 결론

제15장 세계의 펄스 필드 절제 시장

제16장 펄스 필드 절제 시장, 지역별

제17장 펄스 필드 절제 시장, 치료 영역별

제18장 펄스 필드 절제 시장, 제품 컴포넌트별

제19장 심혈관질환용 펄스 필드 절제 시장, 제품 컴포넌트별

제20장 심장혈관 용펄스 필드 절제 시장, 응용 영역별

제21장 심장혈관 용펄스 필드 절제 시장, 절제 근원별

제22장 심장혈관 용펄스 필드 절제 시장, 지역별

제23장 종양 질환용 펄스 필드 절제 시장

제24장 종양성 질환용 펄스 필드 절제 시장, 제품 컴포넌트별

제25장 종양성 질환용 펄스 필드 절제 시장, 암 유형별

제26장 호흡기용 펄스 필드 절제 시장

지역별 장애

제27장 호흡기용 펄스 필드 절제 시장

제품 컴포넌트별 장애

제28장 펄스 필드 절제 : 주요 제품 판매 예측

주요 참여 기업

• 챕터 개요
• Boston Scientific
• Medtronic
• Galvanize Therapeutics
• AngioDynamics

제29장 결론

제30장 부록 1 : 표형식 데이터

제31장 부록 2 : 기업 및 조직 리스트

KSA

영문 목차

영문목차

INTRODUCTION

Pulsed field ablation market, a growing segment of the cardiac ablation market, is anticipated to grow at a compounded annual growth rate (CAGR) of ~40% during the forecast period 2023-2035.

Over the years, medical researchers and practitioners have actively pursued the development of minimally invasive procedures that are less painful, have shorter recovery periods, and offer improved patient outcomes. Such techniques have been able to carve out a niche in the huge atrial fibrillation market. Traditional treatment methods involving surgical procedures, though effective, are accompanied with a wide range of drawbacks, including extensive scarring, longer hospital stays, and a higher risk of complications. As a result, medical experts have turned their attention to ablation therapies, which involve the use of an energy source to destroy the abnormal tissues in the body without the need for invasive surgeries. Currently, several tissue ablation techniques are being employed for the treatment of a wide range of disease indications. However, the conventional ablation methods often rely on thermal energy which can potentially lead to tissue overheating, leading to necrosis of the surrounding healthy tissue. Moreover, these techniques are associated with post-procedural pain and discomfort that impact the patient's quality of life during recovery. As the limitations of traditional ablation methods became apparent, the demand for safer and more effective alternatives led to the emergence of pulsed field ablation (PFA).

Pulsed field ablation harnesses high-voltage electrical pulses delivered in short bursts. This non-thermal ablation process allows for precise targeting of abnormal tissues without causing collateral damage to surrounding healthy cells. By avoiding tissue overheating and charring, PFA ablation significantly reduces the risk of complications and post-procedural discomfort. Despite its applications across diverse medical specialties, pulsed field ablation has particularly shown significant promise in the treatment of cardiac rhythm-related disorders, including atrial fibrillation and ventricular tachycardia. Cardiac ablation through PFA involves the precise application of pulsed field electrical energy to create small scars in the cardiac tissue, effectively blocking irregular electrical signals and restoring a regular heartbeat. According to the Framingham Heart Study, over the past 50 years, the prevalence of atrial fibrillation has increased by three-fold. Owing to the rising disease burden of atrial fibrillation, as well as the ongoing research and development efforts to expand the applications of pulsed field ablation beyond cardiac ablation, the market is anticipated to witness remarkable market growth during the forecast period.

SCOPE OF THE REPORT

"The Pulsed Field Ablation Market: Distribution by Therapeutic Area (Cardiovascular Disorders, Oncological Disorders, Respiratory Disorders and Dermatological Disorders), Product Components (Catheters and Generators), Application Areas (Ablation, and Ablation and Mapping), Source of Ablation (Pulsed Field Energy, Pulsed Field and Radiofrequency Energy, and Pulsed Field and Cryoablation Energy), Key Geographical Regions (North America, Europe and Asia-Pacific): Market Share of Key Companies, Industry Trends and Global Forecasts, 2023-2035 report" features an extensive study of the current market landscape, market size and future opportunities associated with this industry, for the given forecast period. The market research report highlights the efforts of several stakeholders engaged in this emerging and rapidly evolving segment of the medical devices industry. Key takeaways of the pulsed field ablation market report are briefly discussed below.

Surging Prevalence of Atrial Fibrillation, a Key Indication for Pulsed Field Ablation

Atrial Fibrillation (AF) is the most commonly occurring sustained cardiac arrhythmia affecting both men and women, across the globe. Its prevalence tends to rise with age in the general population. , Patients diagnosed with atrial fibrillation face a five-fold higher risk of stroke and a two-fold increased risk of death. According to the Global Burden of Disease, Injury and Risk Factor Study 2019, 59.7 million patients were afflicted with atrial fibrillation, globally. , Since the elderly population is at higher risk of developing atrial fibrillation, the rising ageing world population poses a threat of surged AF prevalence. In the US, around 9% of the population aged 65 and above is suffering from atrial fibrillation. In Europe, atrial fibrillation has emerged as one of the key public health problems, with its prevalence doubling over the last decade. Owing to the rapidly growing ageing population in the European countries, a 70% increase in the number of atrial fibrillation patients has been projected, over the next decade. Further, improved detection and diagnosis of atrial fibrillation has contributed to the growing number of reported cases of this disorder. Moreover, there are multiple modern lifestyle-related risk factors that play a role in the rapidly increasing prevalence of atrial fibrillation. These risk factors include hypertension, diabetes mellitus, smoking, alcohol consumption, obesity, lack of physical activity and psychological stress. Pulsed field ablation, a non-thermal modality, is proving to be a safe procedure for atrial fibrillation patients.

Applications of Pulsed Field Ablation Technology for Cardiac Ablation

At present, several pulsed field ablation devices are available / being developed for therapeutic applications across cardiovascular disorders, oncological disorders, respiratory disorders, and dermatological disorders. In particular, pulsed field ablation devices have demonstrated high efficacy in treating and managing cardiac arrhythmias, while demonstrating selectivity for myocardial tissue and reducing the risk of esophageal injuries, pulmonary vein stenosis and phrenic nerve palsy. Amongst the various types of cardiac arrhythmias, PFA ablation is a proven modality for managing atrial fibrillation (persistent and paroxysmal), which is characterized by irregular beating of the atria (upper chambers) of the heart, due to which blood does not flow to the ventricles (lower chambers). The PFA ablation procedure primarily involves pulmonary vein isolation (PVI) procedure, which aims to restore normal heart rhythm by targeting and isolating the pulmonary veins, which are often the source of abnormal electrical signals that trigger atrial fibrillation. During the PVI procedure, catheters with electrodes are introduced into the heart through blood vessels. These catheters are guided to the pulmonary veins, and the electrodes deliver controlled electrical pulses to the tissue surrounding the pulmonary veins. The electrical pulses create lesions or scar tissue, which block the abnormal electrical signals from propagating to the rest of the atria. It is worth highlighting that beyond atrial fibrillation, the potential application of pulsed field ablation for the treatment of other cardiac arrythmias, including ventricular tachycardia and atrial flutter remains less explored.

Pulsed Field Ablation Transforming Treatment for Oncology and Other Indications

In the field of oncology, pulsed field ablation has been used for the treatment of a wide range of solid tumors, including malignant tumors. Application of electrical pulses can alter the tumor microenvironment, inducing an inhibitory effect on tumors by killing the tumor cells and mobilizing the immune system to suppress tumor growth and invasion. In addition, chronic bronchitis, characterized by inflammation of the airways, can be treated through PFA's targeted ablation of the mucus producing cells lining the inner walls of bronchi. Pulsed field ablation has made significant strides in dermatology, providing an effective approach for precisely removing skin lesions, including both benign and pre-cancerous growths. The tissue selectivity of this type of ablative technology spares the non-cellular collagen foundation of the skin, allowing regeneration of target cells.

Advantages of Pulsed Field Ablation Over Thermal Ablation

Multiple beneficial attributes of pulsed field ablation technology render it a higher safety profile as compared to other thermal ablation techniques. One of the distinguishing features of pulsed field ablation is its tissue-selective functionality, making it particularly valuable in facilitating cardiac ablation procedures by mitigating risks of phrenic palsy and esophageal injury. Even while targeting the cardiomyocytes, this technique spares stromal proteins from alterations, thereby preventing unintended coagulative necrosis and ensuring a more precise and controlled tissue ablation. Further, the delivery of pulsed field energy, whether through one-shot or point-by-point ablation procedures, creates transmural and durable atrial lesions, which effectively reduces the occurrence of pulmonary vein reconnection. , Depending on the specific medical condition and patient's need, electrophysiologists can tailor the electroporation procedure by varying various electrical parameters, such as voltage, number of pulses, pulse width, pulse shape, pulse delay and frequency. It is important to note that pulsed field ablation utilizes apoptosis to induce cell death, leading to a non-inflammatory response and quicker post-procedure recovery time.

Current Pulsed Field Ablation Market Landscape

The pulsed field ablation market features the presence of more than 45 pulsed field ablation devices. Of these, close to 90% of the devices comprise of ablation catheter as an intrinsic part of their product offering. Further, 39 pulsed field ablation devices are currently under various stages of development. In addition, the pulsed field ablation market features 35 companies that possess the necessary expertise to develop and commercialize pulsed field ablation devices. Currently, more than 40% of the pulsed field ablation companies engaged in this industry are small companies, with less than 50 employees. In terms of geographical presence, more than 50% of the pulsed field ablation companies are headquartered in North America. However, it is interesting to note that the majority of the pulsed field ablation devices have received regulatory approval in Europe.

Currently Commercialized Pulsed Field Ablation Devices

At present, seven pulsed field ablation devices have received commercialization approval from various regulatory bodies around the globe. Of these, four devices, namely FARAPULSE™ Pulsed Field Ablation System (Boston Scientific), Affera™ Mapping and Ablation System (Medtronic), RheOx® system (Galvanize Therapeutics) and CENTAURI™ system (Galvanize Therapeutics) are available in Europe. FARAPULSE™ was the first PFA ablation system to receive CE mark in EU to treat atrial fibrillation and remained the only such system till the approval of CENTAURI™ in August 2022. Further, Medtronic's Affera™ is the latest pulsed field ablation catheter to receive CE mark in March 2023.

Further, two pulsed field ablation devices are approved in the US; these are Aliya™ system (Galvanize Therapeutics) for soft tissue ablation and CellFX System (Pulse Biosciences) for dermatological procedures. It is worth highlighting that NanoKnife System developed by AngioDynamics is the only pulsed field ablation device presently approved in China.

Pulsed Field Ablation: Safety and Efficacy in Clinical Studies

More than 70% of the commercialized PFA ablation devices are undergoing clinical trials in regions where they have not yet received approval. The ADVENT pivotal trial, being conducted at 34 locations across US, aims to evaluate the effectiveness of FARAPULSE™ Pulsed Field Ablation by Boston Scientific for the treatment of paroxysmal atrial fibrillation. In addition, a pilot-scale clinical trial, SPACE AF, is being carried out in Canada to evaluate the safety and efficacy of the CENTAURI™ system. , Further, Medtronic's PulseSelect™ Pulsed Field Ablation System is currently being evaluated in PULSED AF, a multi-center, non-randomized, global clinical trial, to assess its effectiveness for the treatment of atrial fibrillation. The device exceeded its performance goal with negligible side effects, thus proving its efficacy. In fact, the clinical study evaluating PulseSelect™ Pulsed Field Ablation System reported a primary adverse events rate of 0.7%, one of the lowest amongst those recorded for any prior FDA Investigational Device Exemption (IDE) trial for atrial fibrillation ablation device. In addition, there were no reported events of esophageal injury, pulmonary vein stenosis or phrenic nerve damage. It is worth highlighting that three pulsed field ablation devices, namely FARAPULSE™ Pulsed Field Ablation System (Boston Scientific), PulseSelect™ Pulsed Field Ablation System (Medtronic) and RheOx® system (Galvanize Therapeutics) have received breakthrough designation from the FDA. ,

Pulsed Field Ablation Market: Cardiovascular Disorders Marget Segment to hold the Largest Market Share

Given the increasing prevalence of atrial fibrillation, high efficacy and safety profile of ablation through irreversible electroporation, the pulsed field ablation market size is anticipated to grow at an annualized rate (CAGR) of nearly 40% during the forecast period 2023-2035. It is worth highlighting that, in terms of therapeutic area, cardiovascular disorders segment is expected to capture the majority market share in the pulsed field ablation market in 2023 and this trend is likely to remain unchanged throughout the forecast period.

Leading Pulsed Field Ablation Companies

Examples of key pulsed field ablation companies (device developers which have also been profiled in this market report) include (in alphabetical order) Abbott, AccuPulse Medical, Acutus Medical, AngioDynamics, Arga Medtech, AtriAN Medical, Aurigen Medical, Biosense Webster, Boston Scientific, CathRx, ElectroPhysiology Frontiers, EnChannel Medical, Galvanize Therapeutics, Hangzhou Dinova EP Technology, Kardium, Medtronic, Mirai Medical, Pulse Biosciences and Tianjin Intelligent Health Medical. This market report includes an easily searchable excel database of all the pulsed field ablation companies worldwide.

Recent Developments

Although the first direct current ablation was performed during the 1980s, the field gained momentum only after 2011, when PFA focused research to treat atrial fibrillation was initiated. Several developments have taken place in the field of pulsed field ablation, over the past few years. Some of these recent initiatives have been mentioned below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that we have been outlined in our analyses.

• In July 2023, the 9th World Congress on Cardiology and Cardiovascular Therapeutics was held in Vancouver, Canada.
• In May 2023, Pulse Biosciences raised an amount of USD 65 million in a private placement round. The round was led by Robert W. Duggan, executive chairman at Pulse Biosciences. The proceeds from the round will be utilized for the development of the company's proprietary Nanosecond Pulsed Field Ablation™ (nsPFA™) technology for the treatment of atrial fibrillation.
• In March 2023, Medtronic received CE mark approval for the Affera™ Mapping and Ablation System for the treatment of atrial fibrillation. The system includes Sphere-9™ Catheter and Affera™ Prism-1 Mapping Software.

The market report presents an in-depth analysis, highlighting the capabilities of various pulsed field ablation companies, across different geographies. Amongst other elements, the market research report features:

• A preface providing an introduction to the full report, Pulsed Field Ablation Market, 2023-2035.
• An outline of the systematic research methodology adopted to conduct the study on pulsed field ablation market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of our findings.
• An overview of economic factors that impact the overall pulsed field ablation market, including historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.
• An executive summary of the key insights captured during our research, offering a high-level view on the current state of the pulsed field ablation market and its likely evolution in the short to mid and long term.
• A general overview of pulsed field ablation, highlighting details on different types of ablation techniques. It also features details regarding various types of thermal and non-thermal ablation techniques. Further, it provides information on the various components of pulsed field ablation system, as well as its historical evolution, mechanism of action, therapeutic applications and advantages.
• An overview of the current market landscape of pulsed field ablation devices based on relevant parameters, such as product components (ablation catheter, ablation generator, mapping software and others), shape of catheter (circular, linear, flower and basket, spherical and annular), configuration of catheter (open loop and closed loop), type of catheter (by irrigation) (irrigated, non-irrigated), catheter shaft diameter (less than 8 Fr, 8-10 Fr and more than 10 Fr), number of electrodes (less than 6, 6-10 and more than 10), electrical polarity (unipolar, bipolar, quadrapolar), source of ablation (PF, PF and RF energy, and PF and Cryoablation energy), status of development (commercialized and under development), application area (ablation only and ablation and mapping), and target therapeutic area (cardiovascular disorders, oncological disorders, respiratory disorders and dermatological disorders). Further, the chapter features landscape of pulsed field ablation device developers on the basis of relevant parameters, including year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia-Pacific), type of developer (industry and non-industry) and company ownership (privately held and publicly listed).
• An insightful product competitiveness analysis of pulsed field ablation devices, based on player strength (based on years of experience, company size and number of devices offered), product competitiveness (based on application area, source of ablation, electrical polarity and special designation received) and status of development.
• Elaborate profiles of prominent pulsed field ablation companies (shortlisted based on most advanced stage of development) engaged in offering PFA ablation devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its financial performance (if available), product portfolio, recent developments and an informed future outlook.
• Tabulated profiles of key pulsed field ablation companies (shortlisted based on stage of development, for North America and Europe, the companies which have products in pilot stage clinical trial have been included, while for Asia-Pacific, companies for which information was available have been profiled) that are engaged in development of PFA ablation devices. Each tabulated profile features an overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives) and information on its product portfolio.
• A detailed analysis of the recent developments and initiatives reported in pulsed field ablation market. The chapter features insightful analysis of the partnerships that have been inked within the global pulsed field ablation market since 2015, based on several relevant parameters such as year of partnership, type of partnership (mergers and acquisitions, product / technology integration agreement, product / technology utilization agreement, product development agreement, distribution agreement, clinical trial agreement, research agreement, service alliance), type of solution (PFA system, mapping system, integrated system, other systems), therapeutic area (cardiovascular disorders, oncological disorders and respiratory disorders), most active players (in terms of number of deals inked) and regional distribution of partnership activity. The chapter also features detailed analysis of funding and investments raised by pulsed field ablation companies, based on relevant parameters such as year of funding, type of funding, amount invested (USD Million), therapeutic area (cardiovascular disorders, oncological disorders and respiratory disorders), most active players (in terms of number of funding instances and amount raised), most active investors (in terms of number of funding instances) and regional distribution of funding.
• An insightful analysis of patents filed / granted for pulsed field ablation since 2009, taking into consideration various relevant parameters, such as type of patent, patent application year, patent publication year, geographical location, type of player, patent age, publication time, top CPC symbols, leading players (in terms of number of patents filed / granted). Further, the chapter includes a detailed patent benchmarking analysis.
• A detailed analysis of global events attended by the companies engaged in the pulsed field ablation industry, based on relevant parameters such as year of event, type of event, event platform, event organizer, location of event, most active players, speakers and designations (in terms of number of events).
• An in-depth analysis of cardiac mapping and navigation device developers, based on relevant parameters such as year of establishment, company size (in terms of number of employees) and location of headquarters. The chapter also features an analysis of the likelihood of partnership of cardiac mapping and navigation device developers with pulsed field ablation device developers.
• An in-depth analysis of the factors that can impact the growth of pulsed field ablation market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.

The key objective of this market report is to provide a detailed market forecast analysis in order to estimate the existing market size and future opportunity for pulsed field ablation companies over the next decade. We have extensively studied the historical market data within this industry, in order to develop a deeper understanding of the evolutionary market trends. Based on multiple parameters, likely adoption trends and through primary validations, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The market report also features the likely distribution of the historical, current and forecasted opportunity within the pulsed field ablation market across various segments, such as therapeutic area (cardiovascular disorders, oncological disorders, respiratory disorders and dermatological disorders), product components (catheter and generator), application area (ablation, and ablation and mapping) and source of ablation (pulsed field energy, pulsed field and radiofrequency energy, and pulsed field and cryoablation energy) and geography (North America, Europe and Asia-Pacific). In addition, this report features the current and forecasted sales revenues of leading device developers engaged in this domain. In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's market growth.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this market report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this market report has been gathered via secondary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

• Annual reports
• Investor presentations
• SEC filings
• Industry databases
• News releases from company websites
• Government policy documents
• Industry analysts' views

While the focus has been on forecasting the market over the forecast period, the market report also provides our independent view of various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

Question 1: What is pulsed field ablation?

Answer: Pulsed field ablation is a non-thermal ablation modality that destabilizes cell membrane by forming irreversible pores, eventually leading to cell death. The current pulsed field ablation technology is an adaptation of direct current ablation, which was first used to treat cardiac arrhythmia in the 1980s.

Question 2: How does PFA ablation work?

Answer: Pulsed field ablation operates on the mechanism of irreversible electroporation. When pulsed electric fields are applied to a cell, its intracellular charged species get redistributed, disrupting the transmembrane potential. This leads to the formation of artificial nanopores, hindering the cell's ability to maintain homeostasis. If the loss of homeostasis is of sufficient magnitude or duration, the cell cannot restore normal function and dies through either immediate necrosis or apoptosis.

Question 3: How is PFA performed?

Answer: Pulsed field ablation delivers short bursts of high amplitude electric current to kill abnormal tissues. In order to perform the ablation, a catheter is introduced into the human body, through a vein (femoral vein, for instance). Then the catheter is directed to the target organ (where ablation is to be performed) to ablate the abnormally functioning cells by creating transmural lesions.

Question 4: What are the benefits of pulsed field ablation?

Answer: Pulsed field ablation offers numerous benefits over conventional ablation techniques. These include:

• High tissue-selectivity
• Significantly less risk of collateral organ damage
• Improved pulmonary vein isolation durability, thereby preventing recurrence of arrhythmia
• Quicker post-procedure recovery
• Reduced procedure duration
• Lower contact dependency

Question 5: What is pulsed magnetic field radiofrequency ablation?

Answer: Pulsed magnetic field radiofrequency ablation is an innovative technology that delivers radiofrequency oscillations at a rate of pulses per second. Such devices offer greater flexibility to electrophysiologists by allowing them to toggle between energy sources, while performing the ablation procedure.

Question 6: When will pulsed field ablation be available?

Answer: Pulsed field ablation is currently available in Europe, with four commercialized devices in the market, of which three are approved for the treatment of atrial fibrillation, while one system is available for treating patients with chronic bronchitis. In the US, no pulsed field ablation device is commercially available for the treatment of atrial fibrillation. However, two PFA systems are approved for other indications in the US.

Question 7: What is the success rate of pulsed field ablation?

Answer: Several clinical studies have proven that the success rate of pulsed field ablation, in terms of freedom from recurrence of cardiac arrhythmias, is relatively higher than conventional ablation techniques. As per the recent results of the PULSED AF clinical trial conducted at 41 locations across the globe, pulsed field ablation device, PulseSelect™ Pulsed Field Ablation System, is associated with success rate of 80% for patients with paroxysmal atrial fibrillation and 81% for the persistent atrial fibrillation patients.

Question 8: Is FARAPULSE FDA approved?

Answer: In 2021, FARAPULSE™ Pulsed Field Ablation System received CE mark approval for commercialization in the European Union (EU). It was the first PFA device to receive market authorization for the treatment of atrial fibrillation. However, it has not yet received approval from the FDA.

Question 9: What is the estimated market growth rate (CAGR) for the pulsed field ablation market?

Answer: The pulsed field ablation market size is anticipated to grow at an annualized rate (CAGR) of nearly 30% during the forecast period 2023-2035.

Question 10: Who are the leading companies in the pulsed field ablation market?

Answer: Examples of key pulsed field ablation companies (device developers which have also been profiled in this market report) include (in alphabetical order) AccuPulse Medical, Acutus Medical, Adagio Medical, AngioDynamics, Arga Medtech, AtriAN Medical, Biosense Webster, Boston Scientific, CardioFocus, CathRx, CRC EP, Galvanize Therapeutics, Gradient Medical, Hangzhou Dinova EP Technology, Kardium, Medtronic, Mirai Medical, Pulse Biosciences and Tianjin Intelligent Health Medical.

CHAPTER OUTLINES

• Chapter 1 is a preface providing an introduction to the full report, Pulsed Field Ablation Market, 2023-2035.

• Chapter 2 is an outline of the systematic research methodology adopted to conduct the study on pulsed field ablation market, providing insights on the various assumptions, methodologies, and quality control measures employed to ensure accuracy and reliability of findings.

• Chapter 3 provides an overview of economic factors that impact the overall pulsed field ablation market, which include historical trends, currency fluctuation, foreign exchange impact, recession, and inflation measurement.

• Chapter 4 is an executive summary of the key insights captured during our research. It offers a high-level view on the current state of the pulsed field ablation market and its likely evolution in the short to mid and long term.

• Chapter 5 provides a general overview of pulsed field ablation, highlighting details on different types of ablation techniques. It also features details regarding various types of thermal and non-thermal ablation techniques. Further, it provides information on the various components of pulsed field ablation system, as well as its historical evolution, mechanism of action, therapeutic applications and advantages.

• Chapter 6 is an overview of the current market landscape of pulsed field ablation devices based on relevant parameters, such as product components (ablation catheter, ablation generator, mapping software and others), shape of catheter (circular, linear, flower and basket, spherical and annular), configuration of catheter (open loop and closed loop), type of catheter (by irrigation) (irrigated, non-irrigated), catheter shaft diameter (less than 8 Fr, 8-10 Fr and more than 10 Fr), number of electrodes (less than 6, 6-10 and more than 10), electrical polarity (unipolar, bipolar, quadrapolar), source of ablation (PF Only, PF and RF and PF and Cryoablation), status of development (commercialized and under development), application area (ablation only and ablation and mapping), and target therapeutic area (cardiovascular disorders, oncological disorders, respiratory disorders and dermatological disorders). Further, the chapter features landscape of pulsed field ablation device developers on the basis of relevant parameters, including year of establishment, company size (in terms of employee count), location of headquarters (North America, Europe and Asia-Pacific), type of developer (industry and non-industry) and company ownership (privately held and publicly listed).

• Chapter 7 presents an insightful product competitiveness analysis of pulsed field ablation devices, based on player strength (based on years of experience, company size and number of devices offered), product competitiveness (based on application area, source of ablation, electrical polarity and special designation received) and status of development.

• Chapter 8 includes elaborate profiles of prominent players (shortlisted based on most advanced stage of development) engaged in offering pulsed field ablation devices. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives), details related to its financial performance (if available), product portfolio, recent developments and an informed future outlook.

• Chapter 9 presents ttabulated profiles of key players (shortlisted based on stage of development, for North America and Europe, the companies which have products in pilot stage clinical trial have been included, while for Asia-Pacific, companies for which information was available have been profiled) that are engaged in development of pulsed field ablation devices. Each tabulated profile features an overview of the company (including information on year of establishment, number of employees, location of headquarters and key executives) and information on its product portfolio.

• Chapter 10 provides a detailed analysis of the recent developments and initiatives reported in pulsed field ablation market. The chapter features insightful analysis of the partnerships that have been inked within the global pulsed field ablation market since 2015, based on several relevant parameters such as year of partnership, type of partnership (mergers and acquisitions, product / technology integration agreement, product / technology utilization agreement, product development agreement, distribution agreement, clinical trial agreement, research agreement, service alliance), type of solution (PFA system, mapping system, integrated system, other systems), therapeutic area (cardiovascular disorders, oncological disorders and respiratory disorders), most active players (in terms of number of deals inked) and regional distribution of partnership activity. The chapter also features detailed analysis of funding and investments raised by pulsed field ablation companies, based on relevant parameters such as year of funding, type of funding, amount invested (USD Million), therapeutic area (cardiovascular disorders, oncological disorders and respiratory disorders), most active players (in terms of number of funding instances and amount raised), most active investors (in terms of number of funding instances) and regional distribution of funding.

• Chapter 11 presents an insightful analysis of patents filed / granted for pulsed field ablation since 2009, taking into consideration various relevant parameters such as type of patent, patent application year, patent publication year, geographical location, type of player, patent age, publication time, top CPC symbols, leading players (in terms of number of patents filed / granted). Further, the chapter includes a detailed patent benchmarking analysis.

• Chapter 12 includes detailed analysis of global events attended by the pulsed field ablation companies, based on relevant parameters such as year of event, type of event, event platform, event organizer, location of event, most active players, speakers and designations (in terms of number of events).

• Chapter 13 includes an in-depth analysis of cardiac mapping and navigation device developers, based on relevant parameters such as year of establishment, company size (in terms of number of employees) and location of headquarters. The chapter also features an analysis of the likelihood of partnership of cardiac mapping and navigation device developers with pulsed field ablation device developers.

• Chapter 14 presents an in-depth analysis of the factors that can impact the growth of pulsed field ablation market. It also features identification and analysis of key drivers, potential restraints, emerging opportunities, and existing challenges.

• Chapter 15 presents a detailed market forecast analysis in order to estimate the existing market size and future opportunity for pulsed field ablation over the next decade. Based on multiple parameters, likely adoption trends and population prevalence of indications, we have provided an informed estimate on the market evolution during the forecast period 2023-2035. The report also features the likely distribution of the historical, current and forecasted opportunity within the pulsed field ablation market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry's growth.

• Chapter 16 provides detailed projections of the historical, current and future pulsed field ablation market across different geographies, namely North America, Europe and Asia-Pacific.

• Chapter 17 provides detailed projections of the historical, current and future pulsed field ablation market across various therapeutic areas, namely cardiovascular disorders, oncological disorders, respiratory disorders, and dermatological disorders.

• Chapter 18 provides detailed projections of the historical, current and future pulsed field ablation market across various product components, namely catheters and generators.

• Chapter 19 provides detailed projections of the historical, current and future pulsed field ablation market for cardiovascular disorders across product components, namely catheters and generators.

• Chapter 20 provides detailed projections of the historical, current and future pulsed field ablation market for cardiovascular disorders across two major application areas, namely ablation and ablation and mapping.

• Chapter 21 provides detailed projections of the historical, current and future pulsed field ablation market for cardiovascular disorders across various sources of ablation, namely pulsed field energy, pulsed field and radiofrequency energy, and pulsed field and cryoablation energy.

• Chapter 22 provides detailed projections of the historical, current and future pulsed field ablation market for cardiovascular disorders across various geographies, namely North America, Europe and Asia-Pacific.

• Chapter 23 provides detailed projections of the historical, current and future pulsed field ablation market for oncological disorders across various geographies, namely North America, Europe and Asia-Pacific.

• Chapter 24 provides detailed projections of the historical, current and future pulsed field ablation market for oncological disorders across various product components, namely catheters and generators.

• Chapter 25 provides detailed projections of the historical, current and future pulsed field ablation market for oncological disorders across various types of cancer, namely soft-tissue ablative cancers, pancreatic cancer, prostate cancer, non-small cell lung cancer and esophageal cancer.

• Chapter 26 provides detailed projections of the historical, current and future pulsed field ablation market for respiratory disorders across various geographies, namely North America, Europe and Asia-Pacific.

• Chapter 27 provides detailed projections of the historical, current and future pulsed field ablation market for respiratory disorders across various product components, namely catheters and generators.

• Chapter 28 provides detailed projections of the current and future pulsed field ablation market for leading players engaged in this industry.

• Chapter 29 summarizes the entire report, highlighting various facts related to contemporary market trends and the likely evolution of the pulsed field ablation market, based on the research and analysis described in the previous chapters.

• Chapter 30 is an appendix, which contains tabulated data and numbers for all the figures included in this report.

• Chapter 31 is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Introduction
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. RESEARCH

METHODOLOGY

• 2.1 Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact / Related

Factors

• 2.7.6. Market Access
• 2.7.7. Healthcare Policies
• 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER

PROJECT SPECIFIC CONSIDERATIONS

• 3.1 Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Future

Estimates

• 3.2.2. Currency Coverage
  • 3.2.2.1. Overview of Major Currencies

Affecting the Market

• 3.2.2.2. Impact of Currency Fluctuations on the Industry
• 3.2.3. Foreign Exchange Impact
  • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
  • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
• 3.2.4. Recession
  • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
• 3.2.5. Inflation
  • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Types of Ablation Techniques
• 5.3. Types of Catheter Ablation Techniques
  • 5.3.1. Thermal Ablation Techniques
    • 5.3.1.1. Radiofrequency Ablation
    • 5.3.1.2. Laser Ablation
    • 5.3.1.3. Microwave Ablation
    • 5.3.1.4. Hydrothermal Ablation
    • 5.3.1.5. High-Intensity Focused Ultrasound Ablation
  • 5.3.2. Non-Thermal Ablation Techniques
    • 5.3.2.1. Cryoablation
    • 5.3.2.2. Mechanico-Chemical Ablation
    • 5.3.2.3. Pulsed Field Ablation
• 5.4. Overview of Pulsed Field Ablation Therapy
  • 5.4.1. Historical Evolution
  • 5.4.2. Mechanism of Action
  • 5.4.3. Therapeutic Applications
  • 5.4.4. Advantages of Pulsed Field Ablation
• 5.5. Concluding Remarks

6. PULSED FIELD ABLATION DEVICES: MARKET LANDSCAPE

• 6.1. Chapter Overview
• 6.2. Pulsed Field Ablation Devices: Overall Market Landscape
  • 6.2.1. Analysis by Product Components
  • 6.2.2. Analysis by Shape of Catheter
  • 6.2.3. Analysis by Configuration of Catheter
  • 6.2.4. Analysis by Type of Catheter (by Irrigation)
  • 6.2.5. Analysis by Catheter Shaft Diameter
  • 6.2.6. Analysis by Number of Electrodes
  • 6.2.7. Analysis by Electrical Polarity
  • 6.2.8. Analysis by Source of Ablation
  • 6.2.9. Analysis by Status of Development
  • 6.2.10. Analysis by Application Area
  • 6.2.11. Analysis by Status of Development and Location of Clinical Trial
  • 6.2.12. Analysis by Target Therapeutic Area and Target Indication
  • 6.2.13. Analysis by Status of Development and Target Therapeutic Area
  • 6.2.14. Analysis by Location of Clinical Trial and Target Therapeutic Area
  • 6.2.15 Analysis by Source of Ablation, Application Area, and Target Therapeutic Area
• 6.3. Pulsed Field Ablation Device Developers: Overall Market Landscape
  • 6.3.1. Analysis by Year of Establishment
  • 6.3.2. Analysis by Company Size
  • 6.3.3. Analysis by Location of Headquarters
  • 6.3.4. Analysis by Company Size and Location of Headquarters (Region)
  • 6.3.5. Analysis by Type of Developer
  • 6.3.6. Analysis by Company Ownership
  • 6.3.7. Analysis by Company

Ownership and Location of Headquarters (Region)

• 6.3.8. Most Active Players: Analysis by Number of Products

7. PRODUCT COMPETITIVENESS ANALYSIS

• 7.1. Chapter Overview
• 7.2. Assumptions and Key Parameters
• 7.3. Methodology
• 7.4. Product Competitiveness Analysis: Pulsed Field Ablation Devices
  • 7.4.1. Pulsed Field Ablation Devices Offered by Players based in North America
  • 7.4.2. Pulsed Field Ablation Devices Offered by Players based in Europe
  • 7.4.3. Pulsed Field Ablation Devices Offered by Players based in Asia-Pacific
• 7.5. Concluding Remarks

8. PULSED FIELD ABLATION DEVICE DEVELOPERS: DETAILED

COMPANY PROFILES

• 8.1. Chapter Overview
• 8.2. Boston Scientific
  • 8.2.1. Company Overview
  • 8.2.2. Financial Information
  • 8.2.3. Pulsed Field Ablation Portfolio
  • 8.2.4. Recent Developments and Future Outlook
• 8.3. Medtronic
  • 8.3.1. Company Overview
  • 8.3.2. Financial Information
  • 8.3.3. Pulsed Field Ablation Portfolio
  • 8.3.4. Recent Developments and Future Outlook
• 8.4. Galvanize Therapeutics
  • 8.4.1. Company Overview
  • 8.4.2. Pulsed Field Ablation Portfolio
  • 8.4.3. Recent Developments and Future Outlook
• 8.5. Pulse Biosciences
  • 8.5.1. Company Overview
  • 8.5.2. Pulsed Field Ablation Portfolio
  • 8.5.3. Recent Developments and Future Outlook
• 8.6. AngioDynamics
  • 8.6.1. Company Overview
  • 8.6.2. Financial Information
  • 8.6.3. Pulsed Field Ablation Portfolio
  • 8.6.4. Recent Developments and Future Outlook
• 8.7. Biosense Webster
  • 8.7.1. Company Overview
  • 8.7.2. Pulsed Field Ablation Portfolio
  • 8.7.3. Recent Developments and Future Outlook
• 8.8. Acutus Medical
  • 8.8.1. Company Overview
  • 8.8.2. Financial Information
  • 8.8.3. Pulsed Field Ablation Portfolio
  • 8.8.4. Recent Developments and Future Outlook
• 8.9. Kardium
  • 8.9.1. Company Overview
  • 8.9.2. Pulsed Field Ablation Portfolio
  • 8.9.3. Recent Developments and Future Outlook

9. PULSED FIELD ABLATION DEVICE DEVELOPERS: TABULATED

COMPANY PROFILES

• 9.1. Chapter Overview
• 9.2. Abbott
• 9.3. AccuPulse Medical
• 9.4. Arga Medtech
• 9.5. AtriAN Medical
• 9.6. AuriGen Medical
• 9.7. CathRx
• 9.8. ElectroPhysiology Frontiers
• 9.9. EnChannel Medical
• 9.10. Hangzhou Dinova EP

Technology

• 9.11. Mirai Medical
• 9.12. Tianjin Intelligent Health

Medical

10. RECENT DEVELOPMENTS AND INITIATIVES

• 10.1 Chapter Overview
• 10.2 Partnerships and

Collaborations

• 10.2.1. Partnership Models
• 10.2.2. Pulsed Field Ablation: Partnerships and Collaborations
• 10.2.3. Analysis by Year of Partnership
• 10.2.4. Analysis by Type of Partnership
• 10.2.5. Analysis by Year and Type of Partnership
• 10.2.6. Analysis by Type of Product
• 10.2.7. Analysis by Type of Partnership and Type of Solution
• 10.2.8. Analysis by Therapeutic Area
• 10.2.9. Analysis by Type of Partnership and Therapeutic Area
• 10.2.10. Most Active Players: Analysis by Number of Partnerships
• 10.2.11. Analysis by Geography
  • 10.2.11.1. Intercontinental and Intracontinental Agreements
  • 10.2.11.2. Local and International Agreements
• 10.3. Funding and Investments
  • 10.3.1. Funding Models
  • 10.3.2. Pulsed Field Ablation: Funding

and Investments

• 10.3.3. Analysis by Year of Investment
  • 10.3.3.1. Cumulative Year-wise Trend of Funding Instances
  • 10.3.3.2. Cumulative Year-wise Trend of Amount Invested
• 10.3.4. Analysis by Type of Funding
  • 10.3.4.1. Analysis of Funding Instances
  • 10.3.4.2. Analysis of Amount Invested
• 10.3.5. Analysis by Year and Type of Funding
  • 10.3.5.1. Analysis of Funding Instances
  • 10.3.5.2. Analysis of Amount Invested
• 10.3.6. Analysis of Funding Instances and Amount Invested by Therapeutic Area
• 10.3.7. Most Active Players: Analysis by Funding Instances
• 10.3.8. Most Active Players: Analysis by Amount Raised
• 10.3.9. Leading Investors: Analysis by Funding Instances
• 10.3.10. Analysis of Funding Instances and Amount Invested by Geography

11. PATENT ANALYSIS

• 11.1. Chapter Overview
• 11.2. Scope and Methodology
• 11.3. Pulsed Field Ablation: Patent Analysis
  • 11.3.1. Analysis by Patent Application Year
  • 11.3.2. Analysis by Patent Publication Year
  • 11.3.3. Analysis by Type of Patent and Patent Publication Year
  • 11.3.4. Analysis by Publication Time
  • 11.3.5. Analysis by Patent Jurisdiction
  • 11.3.6. Analysis by CPC Symbols
  • 11.3.7. Analysis by Type of Applicant
  • 11.3.8. Analysis by Patent Age
  • 11.3.9. Leading Players: Analysis by Number of Patents
  • 11.3.10. Leading Patent Assignees: Analysis by Number of Patents
• 11.4. Pulsed Field Ablation: Patent Benchmarking Analysis
  • 11.4.1. Analysis of Top CPC Codes by Leading Industry Players
  • 11.4.2. Analysis of Top CPC Codes by Publication Time
• 11.5. Pulsed Field Ablation: Patent Valuation

12. GLOBAL EVENTS ANALYSIS

• 12.1. Chapter Overview
• 12.2. Scope and Methodology
• 12.3. Pulsed Field Ablation: Global Events
  • 12.3.1. Analysis by Year of Event
  • 12.3.2. Analysis by Type of Event
  • 12.3.3. Analysis by Year and Type of Event
  • 12.3.4. Analysis by Event Platform
  • 12.3.5. Analysis by Location of Event
  • 12.3.6. Word Cloud Analysis: Evolutionary Trends in Event Agenda / Key Focus Areas
  • 12.3.7. Most Active Event Organizers: Analysis by Number of Events
  • 12.3.8. Most Active Players: Analysis by Number of Events
• 12.4. Global Events: Speaker Analysis
  • 12.4.1. Most Active Speakers: Analysis by Number of Events
  • 12.4.2. Analysis by Designation of Speakers
• 12.5. Concluding Remarks

13. CASE STUDY: POTENTIAL PARTNERS OF PULSED FIELD ABLATION DEVICE DEVELOPERS

• 13.1. Chapter Overview
• 13.2. Cardiac Mapping and Navigation Device Developers
  • 13.2.1 Analysis by Year of Establishment
  • 13.2.2 Analysis by Company Size
  • 13.2.3 Analysis by Location of Headquarters
• 13.3. Likely Partner Analysis
  • 13.3.1. Assumptions and Key Parameters
  • 13.3.2. Methodology
• 13.4. Potential Strategic Partners for Cardiac Pulsed Field Ablation Device Developers
  • 13.4.1. Cardiac Mapping and Navigation Device Developers: Most Likely Partners
  • 13.4.2. Cardiac Mapping and Navigation Device Developers: Likely Partners
  • 13.4.3. Cardiac Mapping and Navigation Device Developers: Less Likely Partners

14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 14.1. Chapter Overview
• 14.2. Market Drivers
• 14.3. Market Restraints
• 14.4. Market Opportunities
• 14.5. Market Challenges
• 14.6. Conclusion

15. GLOBAL PULSED FIELD ABLATION MARKET

• 15.1. Chapter Overview
• 15.2. Forecast Methodology and Key Assumptions
• 15.3. Global Pulsed Field Ablation Market, Historical Trends (2018-2022) and Future

Estimates (2023-2035)

• 15.3.1. Scenario Analysis
• 15.4. Key Market Segmentations
• 15.5. Dynamic Dashboard

16. PULSED FIELD ABLATION MARKET, BY GEOGRAPHY

• 16.1. Chapter Overview
• 16.2. Forecast Methodology and Key Assumptions
• 16.3. North America: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
• 16.4. Europe: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 16.5. Asia-Pacific: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 16.6. Data Triangulation
  • 16.6.1. Insights from Secondary Research
  • 16.6.2. Insights from In-house Repository
  • 16.6.3. Dynamic Dashboard

17. PULSED FIELD ABLATION MARKET, BY THERAPEUTIC AREA

• 17.1. Chapter Overview
• 17.2. Forecast Methodology and Key Assumptions
• 17.3. Cardiovascular Disorders: Historical Trends (2021-2022) and Forecasted Estimates

(2023-2035)

• 17.4. Oncological Disorders: Historical Trends (2018-2022) and Forecasted Estimates

(2023-2035)

• 17.5. Respiratory Disorders: Historical Trends (2020-2022) and Forecasted Estimates

(2023-2035)

• 17.6. Dermatological Disorders: Historical Trends (2022) and Forecasted Estimates

(2023-2035)

• 17.7. Data Triangulation
  • 17.7.1. Insights from Secondary

Research

• 17.7.2. Insights from In-house Repository
• 17.7.3. Dynamic Dashboard

18. PULSED FIELD ABLATION MARKET, BY PRODUCT COMPONENTS

• 18.1. Chapter Overview
• 18.2. Forecast Methodology and Key Assumptions
• 18.3. Catheters: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 18.4. Generators: Historical Trends (2018-2022) and Forecasted Estimates (2023-2035)
• 18.5. Data Triangulation
  • 18.5.1. Insights from Secondary

Research

• 18.5.2. Insights from In-house Repository
• 18.5.3. Dynamic Dashboard

19. PULSED FIELD ABLATION MARKET FOR CARDIOVASCULAR DISORDERS, BY PRODUCT COMPONENTS

• 19.1. Chapter Overview
• 19.2. Forecast Methodology and Key Assumptions
• 19.3. Catheters: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 19.4. Generators: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 19.5. Data Triangulation
  • 19.5.1. Insights from Secondary Research
  • 19.5.2. Insights from In-house Repository
  • 19.5.3. Dynamic Dashboard

20. PULSED FIELD ABLATION MARKET FOR CARDIOVASCULAR

DISORDERS, BY APPLICATION AREA

• 20.1. Chapter Overview
• 20.2. Forecast Methodology and Key Assumptions
• 20.3. Ablation: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 20.4. Ablation and Mapping: Historical Trends (2021-2022) and Forecasted Estimates

(2023-2035)

• 20.5. Data Triangulation
  • 20.5.1. Insights from Secondary Research
  • 20.5.2. Insights from In-house Repository
  • 20.5.3. Dynamic Dashboard

21. PULSED FIELD ABLATION MARKET FOR CARDIOVASCULAR

DISORDERS, BY SOURCE OF ABLATION

• 21.1. Chapter Overview
• 21.2. Forecast Methodology and Key Assumptions
• 21.3. Pulsed Field: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 21.4. Pulsed Field and Radiofrequency: Historical Trends (2021-2022) and Future

Estimates (2023-2035)

• 21.5. Pulsed Field and Cryoablation: Historical Trends (2021-2022) and Future

Estimates (2023-2035)

• 21.6. Data Triangulation
  • 21.6.1. Insights from Secondary Research
  • 21.6.2. Insights from In-house Repository
  • 21.6.3. Dynamic Dashboard

22. PULSED FIELD ABLATION MARKET FOR CARDIOVASCULAR

DISORDERS, BY GEOGRAPHY

• 22.1. Chapter Overview
• 22.2. Forecast Methodology and Key Assumptions
• 22.3. North America: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
  • 22.3.1. US: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
  • 22.3.2. Canada: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 22.4. Europe: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 22.5. Asia-Pacific: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
  • 22.5.1. China: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
  • 22.5.2. Japan: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 22.6. Data Triangulation
  • 22.6.1. Insights from Secondary Research
  • 22.6.2. Insights from In-house Repository
  • 22.6.3. Dynamic Dashboard

23. PULSED FIELD ABLATION MARKET FOR ONCOLOGICAL

DISORDERS, BY GEOGRAPHY

• 23.1. Chapter Overview
• 23.2. Forecast Methodology and Key Assumptions
• 23.3. North America: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 23.4. Europe: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 23.5. Asia-Pacific: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 23.6. Data Triangulation
  • 23.6.1. Insights from Secondary Research
  • 23.6.2. Insights from In-house Repository
  • 23.6.3. Dynamic Dashboard

24. PULSED FIELD ABLATION MARKET FOR ONCOLOGICAL DISORDERS, BY PRODUCT COMPONENTS

• 24.1. Chapter Overview
• 24.2. Forecast Methodology and Key Assumptions
• 24.3. Catheters: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 24.4. Generators: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 24.5. Data Triangulation
  • 24.5.1. Insights from Secondary Research
  • 24.5.2. Insights from In-house Repository
  • 24.5.3. Dynamic Dashboard

25. PULSED FIELD ABLATION MARKET FOR ONCOLOGICAL DISORDERS, BY TYPE OF CANCER

• 25.1. Chapter Overview
• 25.2. Forecast Methodology and Key Assumptions
• 25.3. Soft Tissue Ablative Cancers: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 25.4. Pancreatic Cancer: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 25.5. Prostate Cancer: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 25.6 Non-Small Cell Lung Cancer: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 25.7 Esophageal Cancer: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 25.8 Data Triangulation
  • 25.8.1. Insights from Secondary Research
  • 25.8.2 Insights from In-house Repository
  • 25.8.3. Dynamic Dashboard

26. PULSED FIELD ABLATION MARKET FOR RESPIRATORY

DISORDERS, BY GEOGRAPHY

• 26.1 Chapter Overview
• 26.2. Forecast Methodology and Key Assumptions
• 26.3. North America: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 26.4. Europe: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 26.5. Asia-Pacific: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 26.6. Data Triangulation
  • 26.6.1. Insights from Secondary Research
  • 26.6.2. Insights from In-house Repository
  • 26.6.3. Dynamic Dashboard

27. PULSED FIELD ABLATION MARKET FOR RESPIRATORY

DISORDERS, BY PRODUCT COMPONENTS

• 27.1 Chapter Overview
• 27.2. Forecast Methodology and Key Assumptions
• 27.3. Catheters : Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 27.4. Generators: Historical Trends (2021-2022) and Forecasted Estimates (2023-2035)
• 27.5. Data Triangulation
  • 27.5.1. Insights from Secondary Research
  • 27.5.2. Insights from In-house Repository
  • 27.5.3. Dynamic Dashboard

28. PULSED FIELD ABLATION: SALES FORECAST OF LEADING

PLAYERS

• 28.1. Chapter Overview
• 28.2. Boston Scientific: Pulsed Field Ablation Sales Forecast (2023-2035)
• 28.3. Medtronic: Pulsed Field Ablation Sales Forecast (2023-2035)
• 28.4. Galvanize Therapeutics: Pulsed Field Ablation Sales Forecast (2023-2035)
• 28.5. AngioDynamics: Pulsed Field Ablation Sales Forecast (2023-2035)

29. CONCLUDING REMARKS

30. APPENDIX 1: TABULATED DATA

31. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

관련자료